Compensation for trial related injury: the sequence, not just the principle

Compensation for trial related injury is written into the New Drugs and Clinical Trials Rules, 2019 as a sequence of obligations with fixed time limits. Most sponsors know the principle. Fewer have mapped the sequence, and the sequence is what determines whether a payment is made on time or becomes a finding.

Medical management is separate from compensation, and it starts first

Where an injury occurs to a subject during a clinical trial or a bioavailability or bioequivalence study, the sponsor provides free medical management to that subject as long as required in the opinion of the investigator, or until it is established that the injury is not related to the study, whichever is earlier.

Two features of that sentence do the work. The duration is set by the investigator's opinion, not by the sponsor's assessment and not by a cap. And the alternative ending is a finding of non-relatedness, which is a conclusion someone has to reach and record, not a position a sponsor can simply hold.

The responsibility rests with the sponsor or the person who obtained the permission to conduct the study. Where they fail to provide it, the Central Licencing Authority can act.

Medical management is therefore live from the moment of injury, before any causality determination, before any order, and independent of whether compensation is ultimately payable.

The twenty-four hour report is the start of the clock

Under rule 42, the investigator reports every serious adverse event to the Central Licencing Authority, to the sponsor or its representative holding the permission, and to the Ethics Committee that approved the protocol, within twenty-four hours of occurrence. An investigator who fails to report within that period has to furnish reasons for the delay, to the satisfaction of the Central Licencing Authority, along with the report.

The analysed report follows within fourteen days of the event, to the Central Licencing Authority, the chairperson of the Ethics Committee and the head of the institution, in the format specified at Table 5 of the Third Schedule.

It is worth being blunt about what the twenty-four hour obligation means for study conduct. It sits with the investigator, at the site, on the day. A sponsor whose safety reporting process routes everything through a central mailbox with a working-hours service level has not built a process that meets it, and the reasons for delay will be furnished by an investigator explaining a system the sponsor designed.

Ninety days, then thirty

For a death, the Central Licencing Authority passes orders within ninety days of receiving the report of the serious adverse event. The sponsor or its representative then pays the compensation specified in that order within thirty days of receiving it.

For permanent disability or other injury short of death, the structure is the same: reports go to the Central Licencing Authority, the chairperson of the Ethics Committee and the head of the institution, an order follows within ninety days of receipt of the report, and payment is made within thirty days of receipt of the order.

The consequence for planning is that the paying window is short and it opens on someone else's timing. Ninety days is enough notice to have a process ready. Thirty days is not enough to build one, and it is not enough to discover that the payment has to clear an approval chain nobody has walked through before.

The question to answer while nothing is happening is a dull one: who signs, on what authority, against which budget line, and how long does that take in practice rather than in policy.

What counts as trial related is broader than the drug

The rules list the causes of injury that attract compensation, and the list extends well past an adverse reaction to the investigational product. It includes failure of the investigational product, adverse effects arising from concomitant medication other than standard care that was necessitated as part of the approved protocol, adverse effect on a child in utero because of a parent's participation, and any clinical trial procedure involved in the study leading to a serious adverse event.

That last item is the one most often left out of a sponsor's mental model. A procedure performed because the protocol required it, rather than because the patient's care required it, is within scope. Additional biopsies, additional imaging with contrast, additional venous access for pharmacokinetic sampling: these are protocol procedures, and an event arising from one of them is a trial related injury.

The in utero provision is similarly under-modelled, and it has implications for how contraception requirements and partner pregnancy reporting are written into the protocol in the first place.

Biomedical and health research follows a different route

Where medical management and compensation relate to biomedical and health research overseen by an Ethics Committee under the relevant chapter, they follow the National Ethical Guidelines for Biomedical and Health Research Involving Human Participants rather than the compensation procedure in these rules.

This matters when an organisation runs both kinds of study and assumes one process covers everything. It does not, and the difference is visible in an audit.

What to have ready before you need it

A twenty-four hour reporting route that starts at the site and does not depend on sponsor office hours, with the Ethics Committee as a named recipient rather than a copy.

A named chairperson at every participating committee, confirmed current, because the fourteen day report is addressed to that office.

A payment path that can move funds within thirty days of an order, tested end to end at least once, including the approval chain and the treasury step.

A documented position on medical management: who authorises continuing treatment, on what evidence, and what a finding of non-relatedness has to look like before treatment stops.

A protocol procedures list, maintained alongside the schedule of assessments, marking which procedures exist for the study rather than for the patient. That list is the practical scope of your protocol-procedure exposure, and it is far easier to write while the protocol is being drafted than after an event.